MX361984B - Sales clorhidrato de un compuesto antibiótico. - Google Patents

Sales clorhidrato de un compuesto antibiótico.

Info

Publication number
MX361984B
MX361984B MX2015012170A MX2015012170A MX361984B MX 361984 B MX361984 B MX 361984B MX 2015012170 A MX2015012170 A MX 2015012170A MX 2015012170 A MX2015012170 A MX 2015012170A MX 361984 B MX361984 B MX 361984B
Authority
MX
Mexico
Prior art keywords
hydrochloride salts
antibiotic compound
compounds
relates
compound
Prior art date
Application number
MX2015012170A
Other languages
English (en)
Other versions
MX2015012170A (es
Inventor
Zhang Weijiang
Lee Junning
Cheung Ronnie
Filipov Dimitar
Green Jack
Original Assignee
Theravance Biopharma Antibiotics Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics Ip Llc filed Critical Theravance Biopharma Antibiotics Ip Llc
Publication of MX2015012170A publication Critical patent/MX2015012170A/es
Publication of MX361984B publication Critical patent/MX361984B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un compuesto de fórmula I: (ver Fórmula) donde x se encuentra dentro del rango entre aproximadamente 1 y aproximadamente 2. También, composiciones farmacéuticas que contienen dichos compuestos; procesos para preparar dichos compuestos; y métodos para usar dichos compuestos, por ejemplo, para tratar una infección bacteriana.
MX2015012170A 2013-03-13 2014-03-06 Sales clorhidrato de un compuesto antibiótico. MX361984B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779065P 2013-03-13 2013-03-13
PCT/US2014/021064 WO2014158952A1 (en) 2013-03-13 2014-03-06 Hydrochloride salts of an antibiotic compound

Publications (2)

Publication Number Publication Date
MX2015012170A MX2015012170A (es) 2015-11-30
MX361984B true MX361984B (es) 2018-12-19

Family

ID=50483481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012170A MX361984B (es) 2013-03-13 2014-03-06 Sales clorhidrato de un compuesto antibiótico.

Country Status (32)

Country Link
US (1) US9161990B2 (es)
EP (1) EP2968446B1 (es)
JP (3) JP6482523B2 (es)
KR (1) KR20150126659A (es)
CN (1) CN105120883B (es)
AR (1) AR095044A1 (es)
AU (1) AU2014241481B9 (es)
BR (1) BR112015022716A2 (es)
CA (1) CA2902720A1 (es)
CY (1) CY1119316T1 (es)
DK (1) DK2968446T3 (es)
EA (1) EA027282B1 (es)
ES (1) ES2633964T3 (es)
GE (1) GEP20186874B (es)
HK (1) HK1214524A1 (es)
HR (1) HRP20171188T1 (es)
HU (1) HUE033738T2 (es)
IL (1) IL240663A0 (es)
LT (1) LT2968446T (es)
MD (1) MD4599C1 (es)
ME (1) ME02854B (es)
MX (1) MX361984B (es)
PH (1) PH12015502060A1 (es)
PL (1) PL2968446T3 (es)
PT (1) PT2968446T (es)
RS (1) RS56141B1 (es)
SG (1) SG11201507235YA (es)
SI (1) SI2968446T1 (es)
TW (1) TWI608845B (es)
UA (1) UA115086C2 (es)
WO (1) WO2014158952A1 (es)
ZA (1) ZA201506748B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980537A1 (en) * 2015-03-24 2016-09-29 Elevance Renewable Sciences, Inc. Polyol esters of metathesized fatty acids and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434287A (en) * 1975-02-20 1984-02-28 Ciba-Geigy Corporation Cephalosporin derivatives
AR229883A1 (es) 1978-05-26 1983-12-30 Glaxo Group Ltd Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato
US4626534A (en) 1984-07-23 1986-12-02 Eli Lilly And Company Pharmaceutical formulation
DE3801179A1 (de) 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
JPH0331449A (ja) 1989-06-27 1991-02-12 Yamaha Corp リードフレーム用Ｆｅ―Ｎｉ合金
CA2026516C (en) 1989-09-30 1998-02-17 Yasuo Ishibashi Injectable preparations containing cephalosporin medicament
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
ATE473986T1 (de) * 2003-04-16 2010-07-15 Sandoz Ag Verfahren zur herstellung von cefepim
ES2335013T3 (es) 2003-05-23 2010-03-18 Theravance, Inc. Antibioticos de glucopeptido-cefalosporina reticulados.
US6878868B2 (en) 2003-06-24 2005-04-12 Mcmillan Stacy L. Portable high-hat device
ES2302034T3 (es) 2003-07-11 2008-07-01 Theravance, Inc. Antibioticos de cefalosporina-glicopeptido reticulados.
TWI342312B (en) 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US20080103121A1 (en) 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
FR2932177B1 (fr) 2008-06-06 2012-11-30 Inst Francais Du Petrole Procede d'hydrogenation selective sur un catalyseur contenant de l'or.
JP2010105965A (ja) 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2774094A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin

Also Published As

Publication number Publication date
ZA201506748B (en) 2017-08-30
CY1119316T1 (el) 2018-02-14
EP2968446A1 (en) 2016-01-20
CA2902720A1 (en) 2014-10-02
TWI608845B (zh) 2017-12-21
PL2968446T3 (pl) 2017-11-30
HRP20171188T1 (hr) 2017-10-06
CN105120883A (zh) 2015-12-02
IL240663A0 (en) 2015-10-29
US9161990B2 (en) 2015-10-20
EP2968446B1 (en) 2017-05-03
JP2017082016A (ja) 2017-05-18
KR20150126659A (ko) 2015-11-12
JP2016513642A (ja) 2016-05-16
JP6482523B2 (ja) 2019-03-13
LT2968446T (lt) 2017-07-25
AU2014241481A1 (en) 2015-10-01
JP2018177817A (ja) 2018-11-15
MX2015012170A (es) 2015-11-30
PT2968446T (pt) 2017-07-27
UA115086C2 (uk) 2017-09-11
ES2633964T3 (es) 2017-09-26
MD4599C1 (ro) 2019-06-30
SG11201507235YA (en) 2015-10-29
BR112015022716A2 (pt) 2017-07-18
DK2968446T3 (en) 2017-08-28
RS56141B1 (sr) 2017-10-31
TW201444572A (zh) 2014-12-01
EA027282B1 (ru) 2017-07-31
MD20150101A2 (ro) 2016-02-29
CN105120883B (zh) 2017-11-17
AR095044A1 (es) 2015-09-16
ME02854B (me) 2018-04-20
AU2014241481B9 (en) 2018-02-15
MD4599B1 (ro) 2018-11-30
US20140274877A1 (en) 2014-09-18
SI2968446T1 (sl) 2017-08-31
AU2014241481B2 (en) 2018-02-01
EA201591697A1 (ru) 2016-02-29
GEP20186874B (en) 2018-06-25
HK1214524A1 (zh) 2016-07-29
HUE033738T2 (hu) 2018-01-29
PH12015502060A1 (en) 2016-01-25
WO2014158952A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
MD4602B1 (ro) Inhibitori ai virusului hepatic C
TN2013000434A1 (en) Novel imidazole derivatives useful for the treatment of arthritis
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
MY197698A (en) Oxysterols and methods of use thereof
MD4820C1 (ro) Compuşi dihidroizochinolinonici substituiţi
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
PH12017501019B1 (en) Isoxazole hydromaxamic acid compounds as lpxc inhibitors
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
PH12014501711A1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2015012472A (es) Derivados de manosa para el tratamiento de infecciones bacterianas.
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MY201377A (en) Compounds and methods for treating bacterial infections
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
PH12015502060A1 (en) Hydrochloride salts of an antibiotic compound
MX2015015251A (es) Derivados de la quinolona.
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
TN2014000308A1 (en) Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration